Skip to main content
Abbisko Cayman Limited logo

Abbisko Cayman Limited — Investor Relations & Filings

Ticker · 2256 ISIN · KYG0028A1085 LEI · 655600UAX2YV03PRXN31 HKEX Manufacturing
Open in API
Filings indexed 402 across all filing types
Latest filing 2025-12-16 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2256

About Abbisko Cayman Limited

http://www.abbisko.com

Abbisko Cayman Limited is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule therapies. The company leverages a robust in-house R&D engine and a multi-dimensional discovery platform to advance a rich pipeline focused primarily on oncology, encompassing both precision-oncology and immuno-oncology candidates. Key product candidates include pimicotinib, which has shown positive topline results for the treatment of tenosynovial giant cell tumor (TGCT). Abbisko aims to develop novel treatments that address critical unmet medical needs for patients globally.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS COMPLETES FIRST PATIENT DOSING OF ABSK061, FGFR2/3 INHIBITOR, FOR THE TREATMENT OF ACHONDROPLASIA
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement issued by Abbisko Cayman Limited regarding the clinical trial progress (first patient dosing) of their drug candidate ABSK061. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a board change or dividend notice. As it is a general regulatory announcement regarding company operations and clinical milestones that does not fall into the other specific categories, it is classified as a Regulatory Filing (RNS).
2025-12-16 English
VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTS PRELIMINARY PHASE II RESULTS OF ORAL PD-L1 INHIBITOR ABSK043 COMBINED WITH EGFR INHIBITOR FIRMONERTINIB FOR THE TREATMENT OF NSCLC AT ESMO ASIA 2
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement issued by Abbisko Cayman Limited regarding the presentation of preliminary Phase II clinical trial results for a drug candidate (ABSK043) at a medical conference (ESMO Asia 2025). It follows the standard format for a regulatory announcement on the Hong Kong Stock Exchange, including a disclaimer, company details, and the announcement text. Since it does not fit into specific categories like financial reports, dividends, or director dealings, and is a general corporate disclosure, it is classified as a Regulatory Filing (RNS).
2025-12-08 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, including share capital, share options, and treasury shares. Since it is a recurring regulatory filing regarding capital structure and share movements that does not fit into specific categories like 'Share Issue' (which usually implies a specific event) or 'Director's Dealing', it is best classified as a Regulatory Filing (RNS).
2025-12-03 English
VOLUNTARY ANNOUNCEMENT - IND CLEARANCE FROM THE FDA FOR ORAL SMALL MOLECULE KRAS G12D INHIBITOR ABSK141
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement issued by Abbisko Cayman Limited regarding the FDA clearance of an Investigational New Drug (IND) application for a clinical trial. It does not fit into financial reporting categories like 10-K, IR, or ER, nor does it relate to corporate governance, dividends, or share transactions. As it is a general regulatory announcement regarding company operations and clinical progress that does not fall into the other specific categories, it is classified as a Regulatory Filing (RNS).
2025-12-01 English
VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTS LONGER-TERM EFFICACY AND SAFETY OUTCOMES FROM PHASE III MANEUVER STUDY OF PIMICOTINIB AT CTOS 2025 ANNUAL MEETING
Regulatory Filings Classification · 1% confidence The document is a 'Voluntary Announcement' issued by Abbisko Cayman Limited regarding the presentation of clinical trial results (Phase III MANEUVER study) at a medical conference (CTOS 2025). It provides details on the efficacy and safety of the drug pimicotinib. Since this is a general regulatory announcement regarding company business and clinical progress that does not fit into specific categories like financial reports, dividends, or M&A, it is classified as a Regulatory Filing (RNS).
2025-11-17 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025
Regulatory Filings Classification · 1% confidence The document is a standard ‘FF301’ monthly return to the Hong Kong Exchange under Chapter 19B, detailing authorized, issued, and treasury share movements (repurchases, share options, etc.). It is a recurring regulatory Listing Rule filing rather than a standalone financial report, earnings release, management discussion, or share issue announcement. It does not announce any specific dividend, vote, or M&A event. Therefore it falls under the generic Regulatory Filings category.
2025-11-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.